Saving residual kidney function among haemodialysis patients receiving irbesartan - a double blind randomised study - SAFIR
- Conditions
- We want to investigate if an angiotensin II antagonist (irbesartan) has beneficial effects regarding residual kidney function and heart/vessels among haemodialysis patients.MedDRA version: 9.1Level: LLTClassification code 10049415Term: Renin-angiotensin system inhibition
- Registration Number
- EUCTR2008-001267-11-DK
- Lead Sponsor
- Department of Nephrology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Haemodialysis patient
Haemodialysis for maximum 1 year
Urine volume > 300 ml/24 hours
Informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Known allergy to angiotensin II antagonist or ACE-inhibitor
Acute myocardial infarction in the preceding 3 months
Ejection fraction < 30 %
Systolic blood pressure < 110 mm Hg
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method